| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/03/2013 | CN102258543B Method for processing lucid ganoderma |
| 04/03/2013 | CN102198211B Traditional Chinese medicine composition for treating neurasthenia, and preparation method thereof |
| 04/03/2013 | CN102151274B Method for stable light focusing of fasudil hydrochloride and composition obtained using same |
| 04/03/2013 | CN102127054B 3-(substituted dihydroisoindol-2-yl)-2,6-piperidinedione polymorph and pharmaceutical composite |
| 04/03/2013 | CN102093440B Coproduction process of pig brain protein hydrolysate and monosialoganglioside |
| 04/03/2013 | CN102091281B Smoking-quitting and toxin-reducing medicinal powder and preparation method thereof |
| 04/03/2013 | CN102086195B Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof |
| 04/03/2013 | CN102086182B Petasites tatewakianus Kitam. extract as well as preparation method and application thereof |
| 04/03/2013 | CN102060904B Celosia argentea L. saponin compounds and application thereof |
| 04/03/2013 | CN102047997B Wuyi Mountain rock tea extract, and preparation method and application thereof |
| 04/03/2013 | CN101851170B Chlocibutamine type II crystals |
| 04/03/2013 | CN101528732B 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulators |
| 04/03/2013 | CN101489984B Aminoindan derivative or salt thereof |
| 04/03/2013 | CN101351476B Antibodies with glycosylated in the variable region |
| 04/03/2013 | CN101316587B 取代的吡唑化合物 Substituted pyrazole compound |
| 04/02/2013 | US8410174 Method for treating arthritis |
| 04/02/2013 | US8410148 Method and composition for potentiating an opiate analgesic |
| 04/02/2013 | US8410135 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators |
| 04/02/2013 | US8410132 Modulators of cystic fibrosis transmembrane conductance regulator |
| 04/02/2013 | US8410110 9-(piperazinylalkyl) carbazoles as Bax-modulators |
| 04/02/2013 | US8410053 Methods for treating autoimmune disorders, and reagents related thereto |
| 04/02/2013 | US8409613 Gastric retained gabapentin dosage form |
| 04/02/2013 | US8409584 Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
| 04/02/2013 | US8409575 Antibodies specific for amyloid beta protofibril |
| 04/02/2013 | US8409548 Administration of growth factors for the treatment of CNS disorders |
| 04/02/2013 | CA2723222C Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
| 04/02/2013 | CA2715143C Novel phenylpyrrole derivative |
| 04/02/2013 | CA2602247C Piperazine-substituted benzothiophenes for treatment of mental disorders |
| 04/02/2013 | CA2567489C Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor |
| 04/02/2013 | CA2565683C Substituted azepine derivatives as serotonin receptor modulators |
| 04/02/2013 | CA2550843C Novel phenylalanine derivatives |
| 04/02/2013 | CA2537292C 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| 04/02/2013 | CA2514948C Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
| 04/02/2013 | CA2475633C Heteroaryl compounds useful as inhibitors of gsk-3 |
| 04/02/2013 | CA2470920C Liposomal delivery of vitamin e based compounds |
| 04/02/2013 | CA2457611C Novel molecular target for neurotoxicity |
| 04/02/2013 | CA2396212C Recombinant antibodies to human interleukin-1 beta |
| 04/02/2013 | CA2201282C Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes |
| 03/28/2013 | WO2013044147A1 Vaccine therapy |
| 03/28/2013 | WO2013044092A1 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| 03/28/2013 | WO2013044058A1 Mitochondria-targeted antioxidants for treatment of age-related brain disorders |
| 03/28/2013 | WO2013043985A1 Edible oils to enhance delivery of orally administered steroids |
| 03/28/2013 | WO2013043960A1 Compounds useful as inhibitors of choline kinase |
| 03/28/2013 | WO2013043744A2 Tricyclic compounds useful as neurogenic and neuroprotective agents |
| 03/28/2013 | WO2013043232A2 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer |
| 03/28/2013 | WO2013043125A1 Enterovirus 71 specific antibodies and uses thereof |
| 03/28/2013 | WO2013043085A1 Pharmaceutical substance (variants) and compositions based thereon which exhibit modulatory activity with a commensurate effect |
| 03/28/2013 | WO2013042943A2 Use for glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand |
| 03/28/2013 | WO2013042833A1 Pharmaceutical composition for the prevention or treatment of a prion disease containing an active ingredient in the form of the prnp gene using recombinant adenovirus vector |
| 03/28/2013 | WO2013042782A1 Condensed heterocyclic compound |
| 03/28/2013 | WO2013042684A1 Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases |
| 03/28/2013 | WO2013042139A1 Amide compounds, compositions and applications thereof |
| 03/28/2013 | WO2013042135A1 Heteroaryl compounds as 5-ht4 receptor ligands |
| 03/28/2013 | WO2013042054A1 Buprenorphine for the treatment of acute suicidality |
| 03/28/2013 | WO2013042005A1 N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
| 03/28/2013 | WO2013041962A1 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| 03/28/2013 | WO2013041719A1 Tripeptide kdpt for antiapoptotic treatment |
| 03/28/2013 | WO2013041696A1 Stimulating and invigorating nasal spray and nasal drop |
| 03/28/2013 | WO2013041604A1 Crystal form of asenapine maleate |
| 03/28/2013 | WO2013041499A1 N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors |
| 03/28/2013 | WO2013041480A1 New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments |
| 03/28/2013 | WO2013041472A1 Triazolopyridine compounds as pde10a inhibitors |
| 03/28/2013 | WO2013041239A1 Pkm zeta bindin peptides, peptide derivatives and conjugates, and uses thereof |
| 03/28/2013 | WO2013041238A1 Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders |
| 03/28/2013 | WO2013040801A1 Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof |
| 03/28/2013 | WO2013040649A1 Therapeutics using adipose cells and cell secretions |
| 03/28/2013 | WO2013016193A3 Activators of class i histone deacetlyases (hdacs) and uses thereof |
| 03/28/2013 | WO2013010218A9 Inhibition of clathrin |
| 03/28/2013 | WO2012176172A3 Combination therapy with psd-95 inhibitor for ischemia |
| 03/28/2013 | WO2012173442A9 Composition containing bee venom phospholipase as an active ingredient treating prion disease |
| 03/28/2013 | WO2012166891A3 Mu-opioid receptor binding compounds |
| 03/28/2013 | WO2012166463A3 Aminooxazole inhibitors of cyclin dependent kinases |
| 03/28/2013 | WO2012165925A3 Anti-c-met antibody having hgf activity and use thereof |
| 03/28/2013 | WO2012156968A3 Use of mesenchymal stem cells for the improvement of affective and cognitive function |
| 03/28/2013 | WO2012137146A3 Means for concealing the flavour and smell of peptide hydrolysates |
| 03/28/2013 | WO2012131109A3 Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders |
| 03/28/2013 | US20130079377 Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands |
| 03/28/2013 | US20130079373 Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands |
| 03/28/2013 | US20130079338 Selective NR2B Antagonists |
| 03/28/2013 | US20130079321 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| 03/28/2013 | US20130079317 Methods for treatment of diseases |
| 03/28/2013 | US20130078307 Nicotine-containing pharmaceutical composition |
| 03/28/2013 | US20130078304 Controlled release formulation for treating sleep disorders |
| 03/28/2013 | US20130078237 Cd27l antigen binding proteins |
| 03/28/2013 | US20130078233 Compositions and methods using same for treating amyloid-associated diseases |
| 03/28/2013 | US20130078220 Dopaminergic neuronal survival-promoting factors and uses thereof |
| 03/28/2013 | CA2858033A1 Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof |
| 03/28/2013 | CA2849726A1 Amide compounds, compositions and applications thereof |
| 03/28/2013 | CA2849711A1 Compound having modulatory activity with a commensurate effect, pharmaceutical substance (variants), application of pharmaceutical substance, pharmaceutical and parapharmaceuticalformulation (variants), method of preparation of pharmaceutical compositions |
| 03/28/2013 | CA2849442A1 Compounds useful as inhibitors of choline kinase |
| 03/28/2013 | CA2849279A1 Interomone compositions and their use to modify behavior in different vertebrate species |
| 03/28/2013 | CA2849255A1 A composition and method for treating an autoimmune disease |
| 03/28/2013 | CA2849055A1 N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
| 03/28/2013 | CA2848346A1 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| 03/28/2013 | CA2846758A1 Triazolopyridine compounds as pde10a inhibitors |
| 03/28/2013 | CA2845183A1 Tripeptide kdpt for antiapoptotic treatment |
| 03/28/2013 | CA2844654A1 N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors |
| 03/28/2013 | CA2843211A1 New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments |
| 03/28/2013 | CA2832309A1 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer |
| 03/28/2013 | CA2823548A1 Heteroaryl compounds as 5-ht4 receptor ligands |